Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Plasmodium falciparum acylguanidine 1 (PfACG1), also known as the aspartate-glutamate carrier isoform 1 (PF3D7_0910300), is a conserved protein in the malaria parasite that plays a critical role in mediating resistance to the preclinical antimalarial candidate MMV688533. Identified through whole-genome sequencing of drug-pressured parasite lines, PfACG1 is a member of the solute carrier family 25 (SLC25) and is implicated in essential cellular processes such as intracellular trafficking, lipid utilization, and endocytosis. While PfACG1 is not the primary direct target of the acylguanidine compound MMV688533, specific mutations in the protein, including G98V and W286R, confer low-grade resistance by potentially altering the parasite's metabolic or trafficking pathways. MMV688533 itself is a fast-acting antimalarial that shows high potency against multiple parasite stages and a high barrier to resistance, making it a promising candidate for single-dose malaria cures. PfACG1 is localized to distinct intracellular vesicles, and its characterization has provided valuable insights into the novel mode of action of acylguanidine-based therapeutics. Understanding the function of PfACG1 is essential for monitoring the emergence of resistance and for the further development of next-generation antimalarials targeting the parasite's transport and trafficking machinery.
Resistance determinant; mutations in the protein confer reduced susceptibility to the antimalarial candidate MMV688533.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Plasmodium falciparum acylguanidine 1 (PfACG1) (PfACG1).